These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25386936)

  • 1. Neoadjuvant therapy for breast cancer.
    Zardavas D; Piccart M
    Annu Rev Med; 2015; 66():31-48. PubMed ID: 25386936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant endocrine treatment in primary breast cancer - review of literature.
    Mathew J; Asgeirsson KS; Jackson LR; Cheung KL; Robertson JF
    Breast; 2009 Dec; 18(6):339-44. PubMed ID: 19836953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant use of endocrine therapy in breast cancer.
    Macaskill EJ; Dixon JM
    Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoadjuvant antihormonal treatment of women with breast cancer].
    Tuxen MK; Kamby C; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
    Wong ZW; Ellis MJ
    Oncology (Williston Park); 2004 Apr; 18(4):411-20; discussion 421, 424, 429 passim. PubMed ID: 15134351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based neoadjuvant endocrine therapy for breast cancer.
    Dienstmann R; Bines J
    Clin Breast Cancer; 2006 Oct; 7(4):315-20. PubMed ID: 17092398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoadjuvant systemic therapy in breast cancer].
    Kahán Z; Nikolényi A; Uhercsák G; Thurzó L
    Orv Hetil; 2009 Jan; 150(2):65-71. PubMed ID: 19103557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
    Tao Y; Klause A; Vickers A; Bae K; Ellis M
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):91-5. PubMed ID: 15994076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making.
    Debled M; Auxepaules G; de Lara CT; Garbay D; Brouste V; Bussières E; Mauriac L; MacGrogan G
    Am J Surg; 2014 Nov; 208(5):756-763. PubMed ID: 24814311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant endocrine therapy in breast cancer.
    Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
    Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
    Mamounas EP
    Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer (non-metastatic).
    Rodger A; Stebbing J; Thompson AM
    Clin Evid; 2006 Jun; (15):2360-92. PubMed ID: 16973090
    [No Abstract]   [Full Text] [Related]  

  • 13. Surgical issues surrounding use of aromatase inhibitors.
    Dixon JM; Renshaw L; Murray J; Macaskill EJ; Young O; Miller WR
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):97-103. PubMed ID: 16023854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response.
    Jones RL; Smith IE
    Lancet Oncol; 2006 Oct; 7(10):869-74. PubMed ID: 17012049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug development: neoadjuvant opportunities in breast cancer.
    Rastogi P; Geyer CE; Mamounas EP; DeMichele A
    Am Soc Clin Oncol Educ Book; 2013; ():73-9. PubMed ID: 23714461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach.
    Reinbolt RE; Mangini N; Hill JL; Levine LB; Dempsey JL; Singaravelu J; Koehler KA; Talley A; Lustberg MB
    Semin Oncol Nurs; 2015 May; 31(2):146-55. PubMed ID: 25951743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
    Gralow JR; Burstein HJ; Wood W; Hortobagyi GN; Gianni L; von Minckwitz G; Buzdar AU; Smith IE; Symmans WF; Singh B; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):814-9. PubMed ID: 18258991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of endocrine therapy in the neoadjuvant surgical setting.
    Dixon JM
    Ann Surg Oncol; 2004 Jan; 11(1 Suppl):18S-23S. PubMed ID: 15015705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
    J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.